A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Neuroendocrine Prostate Cancer
DRUG: Tarlatamab
Number of Participants who Experience One or More Treatment-emergent Adverse Events (TEAEs), Day 1 to 12 months|Number of Participants who Experience One or More Treatment-related Adverse Events, Day 1 to 12 months|Number of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs, Baseline to 12 months|Number of Participants who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements, Baseline to 12 months|Number of Participants who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests, Baseline to 12 months|Number of Participants who Experience Dose Limiting Toxicities (DLTs), Baseline to 12 months
Objective Response (OR), OR will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications., Baseline to 12 months|Duration of Response (DOR), Baseline to 12 months|Progression-free Survival (PFS), Baseline to 12 months|Overall Survival (OS), Baseline to 12 months|Disease Control Rate (DCR), Baseline to 12 months|Maximum Serum Concentration (Cmax) of Tarlatamab, Baseline to 12 months|Minimum Serum Concentration (Cmin) of Tarlatamab, Baseline to 12 months|Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of Tarlatamab, Baseline to 12 months|Accumulation Ratio of Tarlatamab, Baseline to 12 months|Half-life (t1/2) of Tarlatamab, Baseline to 12 months
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).